Share on StockTwits

Equities researchers at Mizuho lowered their price target on shares of Salix Pharmaceuticals (NASDAQ:SLXP) from $205.00 to $195.00 in a research report issued on Friday. The firm currently has a “buy” rating on the stock. Mizuho’s price target suggests a potential upside of 46.01% from the company’s current price.

Shares of Salix Pharmaceuticals (NASDAQ:SLXP) traded down 6.06% during mid-day trading on Friday, hitting $125.46. 3,196,235 shares of the company’s stock traded hands. Salix Pharmaceuticals has a 52 week low of $64.93 and a 52 week high of $141.81. The stock’s 50-day moving average is $131.3 and its 200-day moving average is $113.0. The company has a market cap of $7.955 billion and a price-to-earnings ratio of 113.47.

Salix Pharmaceuticals (NASDAQ:SLXP) last issued its quarterly earnings data on Thursday, August 7th. The company reported $1.59 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.69 by $0.10. The company had revenue of $382.00 million for the quarter, compared to the consensus estimate of $397.06 million. During the same quarter last year, the company posted $0.87 earnings per share. Salix Pharmaceuticals’s revenue was up 62.3% compared to the same quarter last year. Analysts expect that Salix Pharmaceuticals will post $6.53 EPS for the current fiscal year.

A number of other firms have also recently commented on SLXP. Analysts at Cantor Fitzgerald upgraded shares of Salix Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday. They now have a $157.00 price target on the stock, up previously from $121.00. Separately, analysts at Deutsche Bank initiated coverage on shares of Salix Pharmaceuticals in a research note on Tuesday, July 22nd. They set a “hold” rating and a $139.00 price target on the stock. Finally, analysts at Zacks upgraded shares of Salix Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Monday, July 21st. They now have a $158.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $133.33.

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.